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Idiopathic Parkinson's disease (IPD) represents a common neurodegenerative disorder. An estimated
2% of the U.S. population, age 65 and older, develops IPD. The number of IPD patients will certainly
increase over the next several decades as the baby-boomers gradually step into this high-risk age
group, concomitant with the increase in the average life expectancy. While many studies have
suggested that industrial chemicals and pesticides may underlie IPD, its etiology remains elusive.
Among the toxic metals, the relationship between manganese intoxication and IPD has long been
recognized. The neurological signs of manganism have received close attention because they
resemble several clinical disorders collectively described as extrapyramidal motor system dysfunction,
and in particular, IPD and dystonia. However, distinct dissimilarities between IPD and manganism are
well established, and it remains to be determined whether Mn plays an etiologic role in IPD. It is
particularly noteworthy that as a result of a recent court decision, methylcyclopentadienyl Mn
tricarbonyl (MMT) is presently available in the United States and Canada for use in fuel, replacing lead
as an antiknock additive. The impact of potential long-term exposure to low levels of MMT
combustion products that may be present in emissions from automobiles has yet to be fully
evaluated. Nevertheless, it should be pointed out that recent studies with various environmental
modeling approaches in the Montreal metropolitan (where MMT has been used for more than 10
years) suggest that airborne Mn levels were quite similar to those in areas where MMT was not
used. These studies also show that Mn is emitted from the tail pipe of motor vehicles primarily as a
mixture of manganese phosphate and manganese sulfate. This brief review characterizes the Mn
speciation in the blood and the transport kinetics of Mn into the central nervous system, a critical
step in the accumulation of Mn within the brain, outlines the potential susceptibility of selected
populations (e.g., iron-deficient) to Mn exposure, and addresses future research needs for Mn. Key
words: iron, manganese, manganese tricarbonyl methylcyclopentadienyl (MMT), transferrin, transport.
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Manganese is an abundant metal. It is ubiqui-
tous in the environment, and it occurs in
water, soil, air, and food. Its essentiality is
critical throughout the life span ofthe mam-
malian organism because it serves as a neces-
sary constituent ofmetalloproteins, including
the mitochondrial enzymes, superoxide dis-
mutase (SOD) and pyruvate carboxylase, and
the astrocyte-specific enzyme, glutamine syn-
thetase (GS) (1,2). In nonoccupationally
exposed individuals, the major route ofexpo-
sure to Mn is via food. Average intake ofMn
is between 2 and 9 mg/day (for an average
70-kg person). Avocados, blueberries, nuts
and seeds, seaweed, egg yolks, whole grains,
legumes, dried peas, and green leafy vegeta-
bles are particularly rich in Mn as is tea.
Substantial tea intake in the diet accounts for
the significantly greater daily intake ofMn in
Britain than in the United States (8.8 and
2.5-4 mg Mn/day, respectively). The pre-
dominant route ofexposure to Mn in occu-
pational settings is by inhalation.
Although only a small fraction of Mn
accumulates in the brain, the latter is criti-
cally affected both by deficiency and excess
of Mn. Mn readily crosses the blood-brain
barrier (BBB) in the developing fetus,
neonate, and the mature mammal (3,4). The
brain normally contains only a small amount
ofMn (5), and both deficiency and excess of
Mn critically affect it. Seizure activity, a hall-
mark ofMn deficiency, is believed to result
from decreased Mn-superoxide dismutase
(Mn-SOD) and GS activities (6), whereas
excessive exposure to Mn is associated with
an irreversible central nervous system (CNS)
disorder characterized by prominent psycho-
logical and neurological disturbances.
Idiopathic Parkinson's disease (IPD)
represents a common neurodegenerative dis-
order. An estimated 2% ofthe U.S. popula-
tion, age 65 and older, develops IPD. The
number of IPD patients will increase over
the next century as the baby-boomers gradu-
ally step into this high-risk age group, con-
comitant with the increase in the average life
expectancy. While the symptoms ofIPD are
clearly distinct from those in manganism (see
below), given the many similarities between
the two disorders, the role of long-term
exposure to Mn in IPD should not be
immediately dismissed.
Initial symptoms associated with mangan-
ism are ofpsychiatric nature, and are clinically
defined as locura manganica. These symptoms
closely resemble those encountered in
schizophrenics, and they include compulsive
or violent behavior, emotional instability, and
hallucinations. Neurological manifestations
usually begin shortly (1-2 months after the
first symptoms) after the appearance ofthose
psychiatric symptoms. The neurological signs
include progressive bradykinesia, dystonia,
and disturbance ofgait. The facial expression
is somewhat fixed, and speech difficulty is fre-
quently observed. Progressively, the patients
develop slurring and stuttering speech with
diminished volume and their voices become
monotonous and sink to a whisper. The
speech is slow and irregular, at times with a
stammer. The clinical picture closely resem-
bles several other clinical disorders collectively
described as extrapyramidal motorsystem dys-
function and, in particular, Parkinson's dis-
ease and dystonia (7-9). At the cellular level,
this condition is associated with increased Mn
concentrations, primarily in those CNS areas
known to contain high concentrations ofnon-
heme iron. These areas comprise the
caudate-putamen, globus pallidus, substantia
nigra, and subthalamic nuclei (10,11).
Nevertheless, unlike in IPD, Mn intoxication
is associatedwith preservation ofthe nigrostri-
atal dopaminergic pathwaydespite clinical evi-
dence of parkinsonian-like deficits (9).
Damage to output pathways downstream to
the nigrostriatal dopaminergic pathway
(globus pallidus) has been implicated as a
potential cause for the parkinsonism-like syn-
drome associated with chronic low-level Mn
exposure (9). Furthermore, in manganism
Lewy bodies are seldom found in the substan-
tia nigra, but they are usually found in
patientswith Parkinson's disease (So.
There are a limited numberofstudies that
address the neurological deficits ofMn expo-
sure in children. Two studies (12,13) indicate
that children who ingested Mn in the drink-
ing water (. 0.241 mg/L) for a minimum of
3 years performed more poorly in school as
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measured by mastery in Chinese, mathemat-
ics performance, and in their overall grade
average (compared with nonexposed stu-
dents). The Mn-exposed children also per-
formed more poorly on a battery of
neurobehavioral tests. Mn exposure levels in
these students were determined byhair analy-
sis. It is noteworthy that no reference was
made in the study (13) to levels oflead and
mercury in the hair, and it is undear ifthese
or perhaps other xenobiotics in the drinking
water (or air) mayhave accounted for the dif-
ferences in the behavioral tests. It also appears
that the researchers have not been blind to
the manganese levels in the hair in two
groups, hence bias in reporting and conclu-
sions cannot be ruled out. These studies
should therefore be cautiously evaluated
within the context ofMn exposure and neu-
robehavioral effects in children.
Transport Kinetics of Mn into
the CNS
Excretory pathways for Mn are well developed
in the neonatal rat, and the avid retention of
tracer quantities ofMn by the neonate are
likely a consequence ofthe scarcity ofthis
essential trace metal in its diet (11). Mn is
required in ahigh amount during infancy and
a sufficient Mn supply is critical for normal
brain development (14). Approximately 80%
ofMn in plasma is bound to J31-globulin and
albumin (15), and a smaller fraction ofMn is
bound to transferrin (To. Mn binding toTfis
time dependent (3,16,12). When complexed
withTf, Mn is exclusively present in the triva-
lent oxidation state (18). At normal plasma Fe
concentrations (0.9-2.8 pg/mL), iron binding
capacity (2.5-4 pgImL), and Tfconcentration
[3 mg/mL, with two metal ion-binding sites
per molecule (Mr 77,000), ofwhich only30%
are occupied by Fe3+], Tfhas 50 jimol/L of
unoccupied Mn3+ binding sites. Tfreceptors
are present on the surface ofthe cerebral capil-
laries (19-21) and endocytosis ofTfoccurs in
capillaries (21). Support for receptor-mediated
endocytosis ofa Mn-Tfcomplex in cultured
neuroblastoma cells was provided by Suarez
and Eriksson (22).
Other ligands for Mn2+ must exist, how-
ever, because plasma that is saturated with
Fe2 , Zn2+, and Cd2+ will bind Mn2+ (23).
Dickinson et al. (24) have addressed the tissue
distribution ofinjected 54Mn (MnCI2) in a
hypotransferrinemic mouse mutant. This
mouse has a mutation in the Tfgene and pro-
duces < 1% ofnormal (wild-type animals) Tf
levels. 54Mn accumulated at abnormally high
levels in the Hp mouse liver, yet its distribu-
tion in the CNS was not altered. These results
reveal that Tfis probably required for proper
targeting ofMn from the liver to other organs,
butindicate that non-Tftransport mechanisms
for Mn must also exist. Unlike many other
metals, Mn2+ does not possess high affinityfor
any particular endogenous ligand. There is
almost no tendency for Mn2+ to complex to
-SH groups and to amines. Not surprisingly,
Mn2+ does not have much variation in its sta-
bility constants for endogenous complexing
ligands (logioK= 3, 4, 3, and 3, for glycine,
cysteine, riboflavin, and guanosine, respec-
tively, where Kis the affinity constant). It is
likely that minute amounts ofMn2+ in plasma
exist, according to the mass action law, as a
chloride complex. The law predicts that at a
constant temperature the product ofthe active
masses on one side ofthe equation when
divided by the product ofthe active masses on
the other side ofthe chemical equation is a
constant, regardless ofthe amounts ofeach
form present at the beginning ofthe action.
While the amount offree Mn in plasma at any
one time must be minute, the mass action law
implies that an infinitesimal amount is always
present. It also holds that ifany Mn2+ leaves
the plasma by dissolving in a lipid membrane,
the protein-Mn2+ complex dissociates to
maintain equlDibrium.
The CNS distribution ofTfreceptors in
relationship to Mn accumulation is notewor-
thy. The thalamic nuclei, the pallidum, and
the substantia nigra contain the highest Mn
concentrations (7). Although the areas with
dense Tfdistribution (25) do not correspond
to the distribution ofMn (or Fe), the fact that
Mn-accumulating areas are efferent to areas of
high Tfreceptor density suggests that these
sites may accumulate Mn via axonal transport
(26). For example, the nucleus accumbens
and the caudate-putamen-two areas that are
abundantly rich in Tfreceptors-provide
efferent fibers to the Mn-rich areas of the
ventral-pallidum, the globus pallidus, and the
substantia nigra (27,28).
Alimited number ofstudies addressed the
transport kinetics ofMn into the CNS. The
studies are largely derived from animal mod-
els (particularly rodents). Although the
rodent (specifically the rat) does not represent
an optimal animal model to study the mecha-
nisms ofMn-induced neurotoxicity, the dis-
tinction between species is not made in this
review, since no evidence exists to substanti-
ate differential transport systems for Mn in
the rodent and the primate. Collectively,
transport studies suggest that MnCI2 enters
the brain from the blood either across the
cerebral capillaries and/or the cerebrospinal
fluid (CSF). At normal plasma concentra-
tions, Mn enters the CNS primarily across
the capillary endothelium, whereas at high
plasma concentrations, transport across the
choroid plexus predominates (14,29-33).
Mn accumulates in the olfactory bulb
and tubercle as well as cerebral cortex, hypo-
thalamus, striatum, and hippocampus after
intranasal injection into the nostril (34-36).
Thus, when inhaled, Mn may be absorbed
via the olfactory pathway. The relative
amounts absorbed and the significance of
this pathway for brain Mn accumulation are
not accurately defined.
The impact ofpotential long-term expo-
sure to lowlevels ofMMT combustion prod-
ucts that may be present in emissions from
automobiles has yet to be fully evaluated.
Using various environmental modeling
approaches, it was estimated that air levels of
Mn in most urban areas in the United States
would increase < 0.02 ,ug/m3 ifMMT were
used in all unleaded gasoline (37). A proba-
bility-based study involving over 900 per-
sonal exposure samples in Montreal (where
MMT has been used for more than 10 years)
confirmed that exposures to airborne Mn
< 2.5 pm in aerodynamic diameter in the
general population are quite low (0.008
pg/m3-median), suggesting that airborne
Mn levels in Montreal were quite similar to
those in areas where MMT was not used
(37). These studies also show that Mn is
emitted from the tailpipe ofmotor vehicles
primarily as a mixture ofmanganese phos-
phate and manganese sulfate and, to a lesser
extent, oxides [e.g., manganese tetroxide
(Mn304)] (51). Moreover, isolated particles
consist ofmanganese, oxygen, phosphorous,
and sulfur and indicate that manganese phos-
phate is the main constituent ofthe residual
particles (38).
The differential distribution in rats
exposed to two forms ofmanganese, MnCl2
and MnO2, administered by intratracheal
injection, gavage, or intraperitoneal injection
were studied by Roels et al. (39). When
administered as MnO2 by intratracheal injec-
tion (mimicking the inhalation route), the
distribution ofMn in the CNS was similar to
that ofMnCl2, accumulating preferentially in
striatum, cortex, and cerebellum. However,
Mn was found at much lower concentrations.
Administration ofmanganese as MnCl2 by
gavage resulted in the same amount ofblood
Mn levels as intratracheal administration of
Mn in the same form. However, unlike intra-
tracheal injection, it did not lead to a signifi-
cant increase of Mn levels in the cortex.
These data suggest that the more soluble
MnCl2 salt accumulated more readily in the
CNS compared with the less soluble MnO2.
Furthermore, the studies indicate that inhala-
tion ofMnCI2 or MnO2 leads to a more pro-
nounced accumulation ofMn in the CNS
compared with oral exposure. While the
effect ofmanganese sulfate on brain levels of
nicotinamide nucleotides has been addressed
(40), thestudylacks toxicokinetic data on the
uptake ofMn into the CNS, and therefore it
could not be used to contrast transport rates
with other forms ofMn. Toxicology studies
were also conducted by administering
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manganese sulfate in feed to groups ofmale
and female F344/N rats and B6C3F1 mice
for 14 days, 13 weeks, and 2 years. However,
these studies were not designed to assess any
neurotoxicity that might have been expected
with chronic exposure to sufficiently high
doses of manganese. Nor did these studies
address the accumulation ofMn in the CNS,
precluding comparisons with other Mn salts
(41). No other studies could be localized on
the toxicokinetics ofmanganese phosphate
and manganese sulfate (and to some extent
manganese tetroxide) vis-a-vis CNS Mn accu-
mulation. Given the impact ofpotential long-
term exposure to low levels of MMT
combustion products, it is imperative that
such studies be carried out.
In summary, how and in what chemical
form Mn is transported across the BBB
remains to be more clearly understood. It
appears that a number oftransport processes
are involved in the transport of Mn across
the BBB:
Facilitated diffusion (passive process
where the driving force for transport is
regulated by participation oftransport
carriers, and the gradient for transport is
provided by the electrochemical potential
ofpermeants) (32.
* Active transport (where the driving force
for transport is regulated by participation
oftransport carriers, and exergonic chemi-
cal reactions are coupled to the permeant
transport) (16,31,32).
* Tf-dependent transport (14,16).
Although nonprotein-bound Mn enters
the brain more rapidly than Tf-bound
Mn (31,32), the question remains as to
which form represents the predominant
mechanism oftransport in situ.
It is clear that different salts ofMn are
transported at differential rates and that the
route ofexposure can govern the concentra-
tions of Mn in various brain regions. With
respect to Mnphosphate, Mn sulfate, and Mn
tetroxide, the primarycombustion products of
MMT (38), no data are presently available on
their transport kinetics across the BBB.
Fe Deficiency: A Potential Risk
Factorfor Mn Neurotoxicity
The competition between Fe and Mn for the
same carrier transport system is noteworthy
and bears significant implications for poten-
tial increased accumulation of CNS Mn in
Fe-deficient populations. Plasma Fe overload
significantly decreases the uptake of Mn
across the BBB, whereas Fe deficiency is asso-
ciated with increased CNS burden of Mn
(3,4). In vivo, intravenous administration of
ferric hydroxide-dextran complex signifi-
cantly inhibits the net uptake ofMn in the
CNS, and high Fe food intake reduces the
concentration of Mn in the CNS (3,42).
Chemically and biochemically, Mn shares
numerous similarities with Fe. For example:
a) both metals are transition elements adja-
cent to each other in the Periodic Table; b)
both carry similar valence charges (2+ and 3+)
in physiological conditions; c) both have simi-
lar ionic radius; d) both strongly bind Tf
(3,14,22), and e) intracellularly, both prefer-
entially accumulate in mitochondria (43,44).
Because ofthese similarities, it is not surpris-
ing that Mn can potentially interact directly
with Fe at the cellular and subcellular levels,
particularly with certain mitochondrial
enzymes that require Fe as a cofactor in their
active catalytic center (56). Such enzymes
include aconitase, NADH-ubiquinone
reductase (Complex I), and succinate dehy-
drogenase (45). Diets high in fat or iron have
been associated with an increased risk for
development of colon cancer. These two
dietary factors are known to decrease
Mn-SOD activity in colonic mucosa, an
enzyme with antioxidative properties (46).
These data are consistent with competition
between these two metals and support the
hypothesis that chronic Fe deficiency may
lead to enhanced accumulation ofMn in the
CNS, potentially leading to aberrant func-
tion. Fe deficiency, defined as an insufficient
supply ofFe to the cells ofthe body after Fe
reserves have been exhausted, is the most
prevalent single nutritional deficiency, affect-
ing over 2 billion people, mostly in the devel-
oping world. Infants and small children and
adolescent, pregnant, and fertile-age women
are most vulnerable (47-53). The majority of
these cases result from inadequate intake of
Fe. The potential for increased CNS Mn
accumulation in this large population and by
inference the potential health risks associated
with elevated brain Mn burden, clearly repre-
sent crucial issues ofexposure and susceptibil-
ity that haveyet to be evaluated.
Mn: Future Research Needs
Studies on Mn transport across the BBB as
well as the mechanisms ofits neurotoxicityare
inconclusive. The following section prioritizes
research needs that are deemed necessary
to define pertinent issues ofMn transport
and neurotoxicity.
The intravenous injection ofMn yields
slower clearance ofthe metal as compared to
oral administration. It implies that more Mn
crosses into tissues, presumably because bolus
injections circumvent first-path metabolism in
the liver. Although Mn transport across the
BBB in its divalent form occurs in conditions
where a large bolus ofMn has been injected
directly into the systemic circulation, it is
yet to be determined if it represents the
physiologically relevant transport species.
Considering that in systemic bolus studies
(where Mn is injected directly into the blood),
the injected concentrations ofMn are orders
ofmagnitude higher than those encountered
physiologically, it is possible that Mn saturates
binding capacities ofplasma-binding proteins
such as albumin and macroglobulin (3). This
may lead to erroneous transport kinetics that
does not represent physiological processes of
Mn transport in blood upon ingestion or to
occupational exposures, where in both condi-
tions the concentrations of Mn in plasma
would be expected to be significantly lower.
Therefore, under experimental conditions of
bolus injections into the blood stream, one
cannot discount the possibility that CNS
transport results from leak pathways, espe-
cially across brain capillaries in those areas that
lack the zonulae occludentes ofthe BBB (i.e.,
circumventricular organs) or the choroid
plexus. It should also be noted that the distri-
bution ofbolus Mn injections (where Mn is
in the divalent oxidation state) is inconsistent
with the results ofpharmacokinetic studies of
Mn distribution upon inhalation and inges-
tion. It is therefore crucial to address the
effects on the blood oftransport ofMn in its
different oxidation states as well as different
exposure routes at physiologically relevant
concentrations ofMn. Additional knowledge
gaps exist with respect to the correlation of
ambient air concentrations ofthe combustion
products ofMMT and blood Mn concentra-
tions. As pointed out earlier, ambient Mn
concentrations in the Montreal area were
quite similar to Mn levels in areas where
MMTwas not used (37,38). Acritical issue to
be resolved relates to the speciation ofMn in
plasma, as well as to its uptake mechanism
into the brain. It is ofinterest that Mn con-
centrates within the globus pallidus and stria-
tum, areas abundantly rich in Fe, raising an
intriguing question about the potential for Tf
to transport Mn in its 3+ oxidation state.
Studies using in vivo microdialysis can shed
novel information on this issue. These studies
will also facilitate regional analysis of Mn
transport within the physiological range of
Mn in plasma.
In vitro (cell culture) studies are needed to
identify the effects of Mn on transmitter
metabolism, uptake, and efflux. It is apparent
that continued focus on dopaminergic inner-
vation is necessary, given that optimal levels of
striatal dopamine do not necessarily preclude
the possibilityofdopaminergic cell loss, repre-
senting upregulation in the function ofthose
cells that have not succumbed to the effect of
Mn. It should also be pointed out that other
neurotransmitters such as y-aminobutyric acid
and glutamate are co-localized to the same
brain areas and therefore may play active roles
in Mn-induced neurotoxicity.
In vitro as well as in vivo studies should
be conducted to address whether the toxicity
of Mn is secondary to disturbances in Fe
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metabolism. With a continuum ofdosages, it
may be possible to ascertain whether Mn is
cytoprotective atlowconcentrations but cyto-
toxic at higher concentrations. Attention
should be directed both to astrocytes and
oligodendrocytes because they accumulate
Mn and Fe preferentially (- 80% oftotal Mn
is in astrocytes and the same percentage ofFe
is localized within oligodendrocytes). Because
both Mn and Fe share similarities in their
chemistry and biochemistry, it is reasonable
to postulate that the mechanisms underlying
Mn distribution both in health and disease
are dependent on Fe homeostasis.
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